Solcitinib 

N/A

Report date: 2024/06/27 20:00:09
NME

Base Information

Drug NameSolcitinib 
Drug Alias NameSolcitinibum索西替尼GSK-2586184GLPG-0778G-154578 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK1
Therapy Area/IndicationsPsoriasisLupus Erythematosus, SystemicColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[21] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcGlaxosmithkline Intellectual Property (No.2) LtdGlaxosmithkline Research & Development Ltd +[5] 
Active IndicationsN/A
Inactive IndicationsPsoriasisLupus Erythematosus, SystemicColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A